Golodirsen injection (VYONDYS 53) | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use

VYONDYS 53: creatinine and urine-assay interpretation

Low muscle mass limits creatinine-based estimation, while excreted drug can interfere with a urine protein assay. Neither issue supplies an automatic renal dose.

Before applying: Use the specified kidney markers, sampling timing and assay precautions. Persistent abnormalities require specialist assessment, not dismissal as artifact.

Also check: VYONDYS 53: creatinine and urine-assay interpretation

Rxlist source

GlobalRPh RX List - Golodirsen (Vyondys 53)

Product / population: VYONDYS 53 in Duchenne muscular dystrophy; low muscle mass limits creatinine-based estimates.
Renal measure: Cystatin C, urine protein testing and potential measured GFR; non-DMD MDRD studies are not a DMD renal dosing rule.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Kidney-toxicity and assay-interference subsections also read (turn997795view5, turn948264view6).

Renal dosing, restrictions and evidence limits

Reduced muscle mass makes creatinine an unreliable kidney marker in DMD. Before therapy, obtain cystatin C, urine dipstick and urine protein/creatinine ratio, and consider measured GFR with an exogenous marker. Monitor urine dipstick monthly and cystatin C/protein-creatinine ratio every three months. Collect urine before infusion or at least 48 hours afterward; persistent abnormalities warrant pediatric nephrology assessment. No specific renal dose adjustment can be recommended from non-DMD adult eGFR studies. The drug can interfere with pyrogallol-red urine protein assays; use appropriate sampling or a noninterfering method. A creatinine-based estimate or isolated urine protein result must be interpreted in this disease and assay context.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/vyondys-53-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - Golodirsen (Vyondys 53)

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

VYONDYS 53 in Duchenne muscular dystrophy; low muscle mass limits creatinine-based estimates.

Renal method: Cystatin C, urine protein testing and potential measured GFR; non-DMD MDRD studies are not a DMD renal dosing rule.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

monitoring and measurement

VYONDYS 53: creatinine and urine-assay interpretation

Low muscle mass limits creatinine-based estimation, while excreted drug can interfere with a urine protein assay. Neither issue supplies an automatic renal dose.

How to use this: Use the specified kidney markers, sampling timing and assay precautions. Persistent abnormalities require specialist assessment, not dismissal as artifact.

GlobalRPh RX List - Golodirsen (Vyondys 53)

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Rxlist source

GlobalRPh RX List - Golodirsen (Vyondys 53)

VYONDYS 53 in Duchenne muscular dystrophy; low muscle mass limits creatinine-based estimates.

Method: Cystatin C, urine protein testing and potential measured GFR; non-DMD MDRD studies are not a DMD renal dosing rule.

Renal dosing, restrictions and evidence limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope GlobalRPh RX List - Golodirsen (Vyondys 53)

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/vyondys-53-drug/

Exact product and population

VYONDYS 53 in Duchenne muscular dystrophy; low muscle mass limits creatinine-based estimates.

RDM39-SCOPE-golodirsen-vyondys53 · Source section: Selected source product scopeRenal section finder

Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist Compare this source

GlobalRPh RX List - Golodirsen (Vyondys 53)

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · VYONDYS 53 in Duchenne muscular dystrophy; low muscle mass limits creatinine-based estimates.

Renal method: Cystatin C, urine protein testing and potential measured GFR; non-DMD MDRD studies are not a DMD renal dosing rule.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.

Renal toxicity or monitoring. On-treatment injury and monitoring instructions are not a baseline renal-dose schedule.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

RDM39-rxlist-golodirsen-vyondys53-0391ec5eb9-C1 · Source locator: Selected renal dosing, use in renal impairment, warnings and clinical pharmacology subsections; see named sections in summary.

Source-specific limits

Kidney-toxicity and assay-interference subsections also read (turn997795view5, turn948264view6).

Source identity and provenance

Source family: product_label_mirror
Source: https://globalrph.com/rx-list/vyondys-53-drug/
Retrieved: 2026-09-07
Renal-function method: Cystatin C, urine protein testing and potential measured GFR; non-DMD MDRD studies are not a DMD renal dosing rule.
Source date/version: Source revision date not established in selected retrieval.
Hash meaning: SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256: 2c6a4d836aa3a1edd3112a858a4f80a38f9e3913d219ba26567230876697573b

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://globalrph.com/rx-list/vyondys-53-drug/
Source retrieval: 2026-09-07. This is not the source publication or label revision date.
Original source type: rxlist summary
Local text SHA-256: d87626aec39ff3c868ad0abfcbbacc903c2d9dca973a73493b4369fa014e29a4
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report